Form 4: Director-Affiliated Funds Sell SION Shares

Funds associated with Sionna Therapeutics Director Bruce Booth sold over 188,000 shares of common stock through pre-arranged trading plans in October 2025.

Summary

• Bruce Booth, a Director of Sionna Therapeutics, Inc. (SION), reported indirect sales of common stock.
• The sales were executed by Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P.
• Transactions occurred on October 10, 13, 14, and 15, 2025.
• Atlas Venture Fund XI, L.P. sold a total of 156,114 shares of common stock.
• Atlas Venture Opportunity Fund II, L.P. sold a total of 32,711 shares of common stock.
• All sales were conducted under Rule 10b5-1 trading plans adopted on February 25, 2025.
• Weighted average sale prices for the transactions ranged from $29.95 to $31.30.
• Following these transactions, Atlas Venture Fund XI, L.P. beneficially owns 2,619,185 shares, and Atlas Venture Opportunity Fund II, L.P. beneficially owns 751,664 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider sales can be perceived negatively, these transactions were executed under pre-arranged 10b5-1 plans, which typically reduce the implication of immediate negative sentiment from the insider.

Positives

• The sales were conducted under pre-arranged Rule 10b5-1 trading plans, indicating a planned divestment strategy rather than a reaction to immediate company news or market conditions.

Negatives

• A significant reduction in indirect beneficial ownership by entities associated with a director, which could be perceived by some investors as a decrease in insider alignment.

Risks

• Potential for market perception of reduced insider confidence, despite the pre-scheduled nature of the 10b5-1 plan, which could exert minor downward pressure on the stock.

Future Outlook

NA

Industry Context

This Form 4 filing reports routine insider transactions and does not provide information directly related to broader industry trends or competitive landscape. The sales by venture funds are typical as companies mature or as part of fund distribution strategies.

Related Party Transactions

• Sales of common stock by Atlas Venture funds, where Director Bruce Booth is a member of the general partner entities, constitute related party transactions. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may note a reduction in indirect beneficial ownership by a director-affiliated entity, which could be interpreted as a slight decrease in insider alignment, though mitigated by the 10b5-1 plan.

Key Dates

Recommendation

The filing reports pre-scheduled sales by director-affiliated funds, which is a routine event for venture capital investors as companies mature. While it reduces insider ownership, the 10b5-1 plan mitigates concerns about immediate negative sentiment. This filing alone does not provide sufficient new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Sionna Therapeutics, SION, Bruce Booth, Form 4, Insider Trading, Stock Sale, Director, Atlas Venture, 10b5-1 Plan